Pathogenic role of IL-17 in psoriasis and psoriatic arthritis.
Psoriasis is a chronic inflammatory skin disorder resulting from a complex network of cytokines and chemokines produced by various immune cell types and tissue cells. Emerging evidence suggests a central role of IL-17 and IL-23/T17 axis in the pathogenesis of psoriasis, giving a rationale for using IL-17-blocking agents as therapeutics. Three agents targeting IL-17 signaling are being studied in Phase III clinical trials: secukinumab and ixekizumab (IL-17 neutralizing agents), and brodalumab (IL-17 receptor antagonist). Preliminary results are highly promising for all anti-IL17 agents, creating fair expectations on this class of agents as the new effective therapeutic approach for the treatment of psoriasis.
Department of Dermatology, University of Rome Tor Vergata, Rome, Italy; Laboratory for Investigative Dermatology, The Rockefeller University, New York, USA.
A
A
Chiricozzi
D000818:Animals; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use; D015535:Arthritis, Psoriatic / Q000188:drug therapy / Q000209:etiology / Q000276:immunology; D002986:Clinical Trials as Topic; D004195:Disease Models, Animal; D004198:Disease Susceptibility; D004311:Double-Blind Method; D006801:Humans; D007239:Infections / Q000209:etiology; D007249:Inflammation / Q000276:immunology; D020381:Interleukin-17 / Q000037:antagonists & inhibitors / Q000502:physiology*; D053759:Interleukin-23 / Q000276:immunology; D051379:Mice; D018448:Models, Immunological; D009369:Neoplasms / Q000209:etiology; D011565:Psoriasis / Q000188:drug therapy / Q000209:etiology* / Q000276:immunology; D016032:Randomized Controlled Trials as Topic; D053722:Receptors, Interleukin-17 / Q000037:antagonists & inhibitors / Q000502:physiology; D016176:T-Lymphocyte Subsets / Q000276:immunology
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D020381:Interleukin-17; D053759:Interleukin-23; D053722:Receptors, Interleukin-17; C571216:brodalumab; C549079:ixekizumab; C555450:secukinumab
Arthritis; Artritis; Aterosclerosis; Atherosclerosis; Brodalumab; IL-17; Ixekizumab; Obesidad; Obesity; Psoriasis; Secukinumab